Latest News

Aggressive Breast Cancer Responds to New Drug

woman looking at mamagram image

In the clinical trial of the new drug, sacituzumab govitecan, about a third of the patients responded to treatment and the effect lasted up to eight months. The research was funded by the drug’s maker.

Source link

Related posts

Study shows the biological clock influences immune response efficiency


Elanco annonce un plein exercice sur des actions supplémentaires et fixe la date de publication de ses bénéfices du T3


Medical News Today: Low-amp electroconvulsive therapy may relieve suicidal thoughts


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy